Overview

CD36 in Nutrient Delivery and Its Dysfunction

Status:
Completed
Trial end date:
2021-07-31
Target enrollment:
Participant gender:
Summary
This proposal will test the hypothesis that chronic treatment with sildenafil with and without the use of nitric oxide substrate, L-arginine, protects against fatty acid induced impairment of endothelial function, improves insulin-stimulated microvascular recruitment, insulin sensitivity and glucose uptake in CD36 rs3211938 G-allele carriers.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Vanderbilt University Medical Center
Collaborator:
Washington University School of Medicine
Treatments:
Citric Acid
Sildenafil Citrate